Literature DB >> 12895454

Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165): studies of grafted and cultured embryonic ventral mesencephalic cells.

Mark R Pitzer1, Caryl E Sortwell, Brian F Daley, Susan O McGuire, Deanna Marchionini, Matthew Fleming, Timothy J Collier.   

Abstract

The present series of experiments investigated the effects of vascular endothelial growth factor (VEGF165) on adult rat striatal cerebrovasculature and embryonic dopamine (DA) neuron allografts in a rat model of Parkinson's disease (PD). We examined VEGF165's ability to (1) alter the vascular network of the adult rat striatum, (2) influence the vascular growth of solid embryonic day 14 (E14) ventral mesencephalic (VM) grafts when placed into a VEGF-pretreated host striatum, (3) alter the function and survival of E14 VM grafts when transplanted into an adult DA-deleted striatum, and (4) influence cell survival and neurite growth in cultures of E14 VM cells. We demonstrate here that a single bolus injection of VEGF165 into the adult rat striatum significantly increases the amount of vasculature in the vicinity of the injection site in a delayed and transient manner when compared to saline controls. Transplanting solid E14 VM grafts into the VEGF165-pretreated striatum resulted in a homogeneous distribution of small blood vessels throughout the graft, a pattern that closely resembles mature adult vasculature. In contrast, grafts in the control condition contained a patchy distribution of heavily dilated vessels. Behavioral measurements indicate that VEGF pretreatment of the intrastriatal graft site accelerates recovery of amphetamine-induced rotational asymmetry in unilateral 6-OHDA lesioned rats. Unexpectedly, however, VEGF pretreatments failed to increase survival of tyrosine hydroxylase-immunoreactive (THir) neurons in the grafts. In contrast to this finding in vivo, adding VEGF165 to glial-reduced E14 rat VM cultures produced a fourfold increase in THir cell survival and a doubling in the length of THir neurites. We conclude that with the proper method of delivery, VEGF165 may prove to be one of several strategies necessary to significantly improve the survival and function of fetal VM tissue grafts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895454     DOI: 10.1016/s0014-4886(03)00100-6

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  14 in total

1.  Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy.

Authors:  Yue-Zu Fan; Wei Sun
Journal:  World J Gastrointest Surg       Date:  2010-04-27

Review 2.  Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression.

Authors:  Neil M Fournier; Ronald S Duman
Journal:  Behav Brain Res       Date:  2011-04-22       Impact factor: 3.332

3.  Cypermethrin alters the expression profile of mRNAs in the adult rat striatum: a putative mechanism of postnatal pre-exposure followed by adulthood re-exposure-enhanced neurodegeneration.

Authors:  Manindra Nath Tiwari; Anand Kumar Singh; Sonal Agrawal; Satya Prakash Gupta; Anurag Jyoti; Rishi Shanker; Om Prakash; Mahendra Pratap Singh
Journal:  Neurotox Res       Date:  2012-04-21       Impact factor: 3.911

Review 4.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

Review 5.  VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration.

Authors:  Peter Carmeliet; Carmen Ruiz de Almodovar; Ruiz de Almodovar Carmen
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

Review 6.  Induced pluripotent stem cells and Parkinson's disease: modelling and treatment.

Authors:  Xiaoyun Xu; Jinsha Huang; Jie Li; Ling Liu; Chao Han; Yan Shen; Guoxin Zhang; Haiyang Jiang; Zhicheng Lin; Nian Xiong; Tao Wang
Journal:  Cell Prolif       Date:  2016-01-08       Impact factor: 6.831

Review 7.  Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis.

Authors:  Ana Catarina Pronto-Laborinho; Susana Pinto; Mamede de Carvalho
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

8.  Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.

Authors:  Enara Herrán; Catalina Requejo; Jose Angel Ruiz-Ortega; Asier Aristieta; Manoli Igartua; Harkaitz Bengoetxea; Luisa Ugedo; Jose Luis Pedraz; Jose Vicente Lafuente; Rosa Maria Hernández
Journal:  Int J Nanomedicine       Date:  2014-05-27

9.  Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease.

Authors:  Torsten Falk; Shiling Zhang; Scott J Sherman
Journal:  Mol Neurodegener       Date:  2009-12-10       Impact factor: 14.195

Review 10.  Brain homeostasis: VEGF receptor 1 and 2-two unequal brothers in mind.

Authors:  Ina M Wittko-Schneider; Fabian T Schneider; Karl H Plate
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.